HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLOUDBREAK-B

1.780

+0.1106.59%

Volume:425.50K

Turnover:725.50K

Market Cap:1.51B

PE:-8.54

High:1.780

Open:1.690

Low:1.650

Close:1.670

52wk High:9.740

52wk Low:1.600

Shares:850.00M

HK Float Shares:850.00M

Volume Ratio:1.07

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.209

ROE:--

ROA:-44.38%

PB:-0.58

PE(LYR):-8.54

PS:18.85

Loading ...

Overview Company News Filings

Cloudbreak Pharma Inc - Phase 3 Data for Cbt-001 Anticipated in Q4 2026

THOMSON REUTERS

Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment With FDA on Phase 3 Path Forward for Cbt-004

THOMSON REUTERS

Cloudbreak Pharma Inc - to Complete Toxicity Studies in 2026 and Initiate Phase 3 in 2027

THOMSON REUTERS

Cloudbreak Pharma Grants 3 Million RSUs Tied to $100 Million Business Development Milestone

CLOUDBREAK-B Grants 8 Million Restricted Share Units Under Post-IPO Equity Incentive Plan

Cloudbreak Pharma Grants 8 Million Restricted Share Units Under Post-IPO Incentive Scheme

CLOUDBREAK-B (02592) Has Fully Paid the Settlement Amount to Cedar Wealth According to the Terms and Conditions of the Settlement Agreement

Cloudbreak Pharma Settles Legal Proceedings with Cedar Wealth

Cloudbreak Pharma Inc - Settlement of Legal Proceedings

THOMSON REUTERS

CLOUDBREAK-B (02592): Court Orders Judicial Preservation of CLOUDBREAK Guangzhou's Bank Account at ICBC Until November 30

BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 December

Court Freezes Cloudbreak Pharma Subsidiary’s Bank Account in Legal Dispute

Cloudbreak Pharma Inc - Court Orders Preservation of Cloudbreak Guangzhou's RMB2.55 Mln Account Till Nov 30, 2026

THOMSON REUTERS

Cloudbreak Pharma's US Unit Submits Application for Juvenile Myopia Drug in China

MT Newswires Live

CLOUDBREAK-B (02592) Successfully Submits CBT-009 New Drug Clinical Trial Application to Drug Review Center

Cloudbreak Pharma Inc - Unit Submitted Ind Application for Cbt-009 to Center for Drug Evaluation to Nmpa

THOMSON REUTERS

Cloudbreak Pharma Submits IND Application for CBT-009 to China CDE

Cloudbreak Pharma's Cornerstone Investor to Extend IPO Share Lock-Up; Shares Plunge 16%

MT Newswires Live

Hong Kong Stocks Movement | CLOUDBREAK-B (02592) Plunges Over 18%, Hits New Listing Low as Lock-up Expires Today

Cloudbreak-B (02592) Issues 1.785 Million Shares Under 2023 Equity Incentive Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02592/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"CLOUDBREAK-B","latestPrice":1.78,"timestamp":1774858100006,"preClose":1.67,"halted":0,"volume":425500,"delay":0,"changeRate":0.06586826347305395,"floatShares":850000000,"shares":850000000,"eps":-0.208525,"marketStatus":"Closed","change":0.11,"latestTime":"03-30 16:08:20","open":1.69,"high":1.78,"low":1.65,"amount":725500,"amplitude":0.077844,"askPrice":1.78,"askSize":1000,"bidPrice":1.68,"bidSize":12500,"shortable":3,"etf":0,"ttmEps":-0.386,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774920600000},"marketStatusCode":5,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":1.67,"openAndCloseTimeList":[[1774834200000,1774843200000],[1774846800000,1774857600000]],"volumeRatio":1.072869,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":850000000,"roa":"-44.38%","roe":"--","lyrEps":-0.208525,"volumeRatio":1.072869,"shares":850000000,"dividePrice":0,"high":1.78,"amplitude":0.077844,"preClose":1.67,"low":1.65,"week52Low":1.6,"pbRate":"-0.58","psRate":"18.85","week52High":9.74,"institutionHeld":0,"latestPrice":1.78,"committee":0.851852,"eps":-0.208525,"divideRate":0,"volume":425500,"delay":0,"ttmEps":-0.386,"open":1.69,"prevYearClose":5.2,"prevWeekClose":1.67,"prevMonthClose":2.23,"prevQuarterClose":5.2,"fiveDayClose":1.73,"twentyDayClose":2.04,"sixtyDayClose":5.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2026-03-27","current":-4.430052,"percent":1,"low":-24.505522,"twenty":-12.631386,"median":-6.530805,"eighty":-5.600393,"high":-4.279308,"avg":-9.189277,"sd":4.526709,"marketCap":1400951099},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-29","current":-5.503941,"twenty":-6.295753,"median":-5.870846,"eighty":-5.538055,"marketCap":4253186871},{"date":"2025-09-05","current":-5.413205,"twenty":-6.239682,"median":-5.742284,"eighty":-5.49926,"marketCap":4186075441},{"date":"2025-09-12","current":-12.640894,"twenty":-6.350655,"median":-5.870846,"eighty":-5.508123,"marketCap":4118964011},{"date":"2025-09-19","current":-12.711577,"twenty":-6.612702,"median":-6.004685,"eighty":-5.525012,"marketCap":4135741868},{"date":"2025-09-26","current":-11.804503,"twenty":-12.358821,"median":-6.058573,"eighty":-5.527436,"marketCap":3842129362},{"date":"2025-10-03","current":-6.439136,"twenty":-12.191113,"median":-6.134046,"eighty":-5.53457,"marketCap":2096453591},{"date":"2025-10-10","current":-5.988337,"twenty":-11.881825,"median":-6.134089,"eighty":-5.548508,"marketCap":1949083838},{"date":"2025-10-17","current":-12.3346,"twenty":-12.21981,"median":-6.187936,"eighty":-5.561014,"marketCap":4009907937},{"date":"2025-10-24","current":-11.844495,"twenty":-12.25273,"median":-6.279578,"eighty":-5.580054,"marketCap":3850518291},{"date":"2025-10-31","current":-12.15705,"twenty":-12.335851,"median":-6.333467,"eighty":-5.585568,"marketCap":3951185436},{"date":"2025-11-07","current":-11.838569,"twenty":-12.273198,"median":-6.424535,"eighty":-5.601607,"marketCap":3850518291},{"date":"2025-11-14","current":-11.510378,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"marketCap":3741462218},{"date":"2025-11-21","current":-12.23865,"twenty":-12.234818,"median":-6.500592,"eighty":-5.630174,"marketCap":3984741151},{"date":"2025-11-28","current":-21.343443,"twenty":-12.412307,"median":-6.613869,"eighty":-5.677994,"marketCap":6946032996},{"date":"2025-12-05","current":-20.614529,"twenty":-12.626633,"median":-6.790202,"eighty":-5.718633,"marketCap":6711142992},{"date":"2025-12-12","current":-17.961539,"twenty":-12.716498,"median":-11.142834,"eighty":-5.735493,"marketCap":5847083331},{"date":"2025-12-19","current":-14.819321,"twenty":-12.837409,"median":-11.27102,"eighty":-5.75741,"marketCap":4823634025},{"date":"2025-12-24","current":-14.055026,"twenty":-12.984934,"median":-11.600706,"eighty":-5.767869,"marketCap":4571966163},{"date":"2026-01-02","current":-11.620216,"twenty":-12.995771,"median":-11.729724,"eighty":-5.769371,"marketCap":3783406861},{"date":"2026-01-09","current":-7.540769,"twenty":-12.961935,"median":-11.510378,"eighty":-5.972321,"marketCap":2457956120},{"date":"2026-01-16","current":-8.049692,"twenty":-12.941587,"median":-11.169175,"eighty":-5.988337,"marketCap":2625734695},{"date":"2026-01-23","current":-6.609576,"twenty":-12.863288,"median":-10.620058,"eighty":-5.996682,"marketCap":2155954686},{"date":"2026-01-30","current":-6.294491,"twenty":-12.820156,"median":-9.452561,"eighty":-6.004685,"marketCap":2055287541},{"date":"2026-02-06","current":-5.800172,"twenty":-12.797534,"median":-8.075865,"eighty":-6.004685,"marketCap":1895897895},{"date":"2026-02-13","current":-5.772062,"twenty":-12.788929,"median":-7.957902,"eighty":-5.976779,"marketCap":1887508966},{"date":"2026-02-20","current":-5.722622,"twenty":-12.762909,"median":-7.89408,"eighty":-5.899654,"marketCap":1870731109},{"date":"2026-02-27","current":-5.716309,"twenty":-12.718958,"median":-7.540769,"eighty":-5.819712,"marketCap":1870731109},{"date":"2026-03-06","current":-5.592845,"twenty":-12.7039,"median":-6.802294,"eighty":-5.77076,"marketCap":1828786465},{"date":"2026-03-13","current":-5.252211,"twenty":-12.674344,"median":-6.763399,"eighty":-5.752368,"marketCap":1719730391},{"date":"2026-03-20","current":-4.787506,"twenty":-12.644727,"median":-6.625153,"eighty":-5.711698,"marketCap":1568729674},{"date":"2026-03-27","current":-4.279308,"twenty":-12.631386,"median":-6.530805,"eighty":-5.600393,"marketCap":1400951099}],"updateTime":1774853170727},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02592\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606841037","title":"Cloudbreak Pharma Inc - Phase 3 Data for Cbt-001 Anticipated in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606841037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606841037?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA6BRTWL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2606784984","title":"Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment With FDA on Phase 3 Path Forward for Cbt-004","url":"https://stock-news.laohu8.com/highlight/detail?id=2606784984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606784984?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA6BRTWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2606476784","title":"Cloudbreak Pharma Inc - to Complete Toxicity Studies in 2026 and Initiate Phase 3 in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2606476784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606476784?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518804,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUA6BRTWL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2605459436","title":"Cloudbreak Pharma Grants 3 Million RSUs Tied to $100 Million Business Development Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2605459436","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605459436?lang=en_us&edition=fundamental","pubTime":"2026-01-22 12:11","pubTimestamp":1769055106,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced a supplemental grant of 3,000,000 Restricted Share Units  under its Post-IPO Share Incentive Scheme. The RSUs have a performance target tied to the Group signing business development agreements totaling US$100 million in combined upfront payments and potential milestone payments. The performance target can be met in whole or in part based on the value of signed agreements, with RSUs vesting pro-rata as milestones are reached. The grant involves Whitcup Life Sciences LLC, a service provider wholly-owned by Dr. Scott Whitcup, which offers research, development, and business development services to the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDLc2xfT3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1127281663","title":"CLOUDBREAK-B Grants 8 Million Restricted Share Units Under Post-IPO Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1127281663","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127281663?lang=en_us&edition=fundamental","pubTime":"2026-01-18 17:32","pubTimestamp":1768728720,"startTime":"0","endTime":"0","summary":"On January 16, 2026, the company announced that it has granted a total of 8 million restricted share units under its post-initial public offering equity incentive plan. These units, equivalent to 8...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2603969685","title":"Cloudbreak Pharma Grants 8 Million Restricted Share Units Under Post-IPO Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2603969685","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603969685?lang=en_us&edition=fundamental","pubTime":"2026-01-16 17:09","pubTimestamp":1768554563,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced the grant of restricted share units  under its Post-IPO Equity Incentive Scheme. The company will grant 5,000,000 RSUs to one employee and 3,000,000 RSUs to one service provider, with the grant date set for 16 January 2026. Any unvested RSUs will be forfeited if the grantee leaves the company or is found, in the company’s view, to have materially breached employment terms or failed to meet required performance standards. No financial assistance was provided to grantees to facilitate the purchase of shares under this scheme.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service oper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL1SWYxM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1181823282","title":"CLOUDBREAK-B (02592) Has Fully Paid the Settlement Amount to Cedar Wealth According to the Terms and Conditions of the Settlement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1181823282","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181823282?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:36","pubTimestamp":1768480586,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced details regarding, among other matters, legal proceedings initiated by Cedar Wealth against the company's indirectly wholly-owned subsidiary, CLOUDBREAK Guangzhou. On...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2603024986","title":"Cloudbreak Pharma Settles Legal Proceedings with Cedar Wealth","url":"https://stock-news.laohu8.com/highlight/detail?id=2603024986","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603024986?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:19","pubTimestamp":1768479573,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced the settlement of legal proceedings related to a dispute with Cedar Wealth. The case involved an asset preservation order on Cloudbreak Guangzhou, a wholly owned subsidiary, which froze approximately RMB2.55 million in its bank account following arbitration initiated by Cedar Wealth. The company stated that the settlement is not expected to have a material adverse impact on its overall business, operations, or cash flow. Business and operations remain normal, and shareholders are advised to exercise caution when dealing in the company’s shares. Further updates will be provided as appropriate in accordance with regulatory requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDLbhr5LH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2603608602","title":"Cloudbreak Pharma Inc -  Settlement of Legal Proceedings","url":"https://stock-news.laohu8.com/highlight/detail?id=2603608602","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603608602?lang=en_us&edition=fundamental","pubTime":"2026-01-15 20:18","pubTimestamp":1768479532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nFWN3YG0C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1157588045","title":"CLOUDBREAK-B (02592): Court Orders Judicial Preservation of CLOUDBREAK Guangzhou's Bank Account at ICBC Until November 30","url":"https://stock-news.laohu8.com/highlight/detail?id=1157588045","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157588045?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:58","pubTimestamp":1767797915,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on January 6, 2026, CLOUDBREAK Biopharmaceutical Technology (Guangzhou) Co., Ltd., an indirect wholly-owned subsidiary, received a notice issued by the Guangzhou...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","161121","BK1161"],"gpt_icon":0},{"id":"2601046658","title":"BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 December","url":"https://stock-news.laohu8.com/highlight/detail?id=2601046658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601046658?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:57","pubTimestamp":1767797842,"startTime":"0","endTime":"0","summary":"BRIEF-Cloudbreak Pharma Inc Says Unit Receives Court Notice Dated 24 DecemberJan 7  - Cloudbreak Pharma Inc 2592.HK:UNIT RECEIVES COURT NOTICE DATED 24 DECEMBERCOURT ORDERS PRESERVATION OF CLOUDBREAK GUANGZHOU'S RMB2.55 MILLION ACCOUNT TILL NOV 30, 2026Further company coverage: 2592.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y816E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2601280170","title":"Court Freezes Cloudbreak Pharma Subsidiary’s Bank Account in Legal Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2601280170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601280170?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:47","pubTimestamp":1767797265,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Subsidiary Cloudbreak Guangzhou Faces Legal Proceedings and Asset Preservation Order. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL4qWTwM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2601801792","title":"Cloudbreak Pharma Inc - Court Orders Preservation of Cloudbreak Guangzhou's RMB2.55 Mln Account Till Nov 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601801792?lang=en_us&edition=fundamental","pubTime":"2026-01-07 22:47","pubTimestamp":1767797255,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y816E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2601962538","title":"Cloudbreak Pharma's US Unit Submits Application for Juvenile Myopia Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2601962538","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601962538?lang=en_us&edition=fundamental","pubTime":"2026-01-06 18:50","pubTimestamp":1767696614,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma's  US unit, ADS Therapeutics, submitted an investigational new drug application for CBT-009 to China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The clinical-stage ophthalmology biotechnology company developed the drug for the treatment of juvenile myopia in children and adolescents aged 5 to 19.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02592","BK1161"],"gpt_icon":0},{"id":"1120737026","title":"CLOUDBREAK-B (02592) Successfully Submits CBT-009 New Drug Clinical Trial Application to Drug Review Center","url":"https://stock-news.laohu8.com/highlight/detail?id=1120737026","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120737026?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:47","pubTimestamp":1767689220,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that its wholly-owned subsidiary, ADS Therapeutics LLC (ADS USA), incorporated in Delaware, United States, has successfully submitted a new drug clinical trial...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","02592","BK4090","BK1161"],"gpt_icon":0},{"id":"2601686779","title":"Cloudbreak Pharma Inc -  Unit Submitted Ind Application for Cbt-009 to Center for Drug Evaluation to Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2601686779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601686779?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:39","pubTimestamp":1767688761,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y616N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"gpt_icon":0},{"id":"2601867179","title":"Cloudbreak Pharma Submits IND Application for CBT-009 to China CDE","url":"https://stock-news.laohu8.com/highlight/detail?id=2601867179","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601867179?lang=en_us&edition=fundamental","pubTime":"2026-01-06 16:38","pubTimestamp":1767688727,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. has announced that its wholly-owned subsidiary, ADS Therapeutics LLC, has successfully submitted an Investigational New Drug  application for CBT-009 to the Center for Drug Evaluation  of the National Medical Products Administration  in China. This milestone marks a significant step in the clinical development process for CBT-009, paving the way for potential Phase III clinical trials in the Chinese market. The company will continue to monitor the evaluation progress and update shareholders and investors as appropriate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong K","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL7wb7SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0},{"id":"2601009050","title":"Cloudbreak Pharma's Cornerstone Investor to Extend IPO Share Lock-Up; Shares Plunge 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601009050","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601009050?lang=en_us&edition=fundamental","pubTime":"2026-01-05 16:30","pubTimestamp":1767601825,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma  said its cornerstone investor, Wealth Strategy, will extend the lock-up undertakings for the shares it subscribed to during the firm's IPO to July 2, according to a Jan. 2 Hong Kong bourse filing.Shares of the clinical-stage ophthalmology biotechnology company were down nearly 16% in Monday afternoon trading.The lock-up period was supposed to expire Jan. 3, the filing said.As of Monday, Wealth Strategy holds over 15.5 million shares in the firm, or a 1.84% holding.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09799","BK4595","MST","LMI3.UK","3LMI.UK","3SMI.UK","09399","MSTU","MSTK","MSTX","MTYY","MSTY.UK","MSTP","MSOO","SMI3.UK","MSTW","MSST","BK4516","BK4585","MSTY","APED","BK1161","MSII","BK4023","MSDD","WNTR","07799","BK4600","07399","MSTZ","SMST","IMST","BK4588","02592","BK4596"],"gpt_icon":0},{"id":"1101251542","title":"Hong Kong Stocks Movement | CLOUDBREAK-B (02592) Plunges Over 18%, Hits New Listing Low as Lock-up Expires Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1101251542","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101251542?lang=en_us&edition=fundamental","pubTime":"2026-01-05 09:56","pubTimestamp":1767578203,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) plummeted more than 18%, hitting a new low since its listing at HKD 3.69 during the trading session. As of the time of writing, the stock was down 18.18%, trading at HKD 3.69,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"gpt_icon":0},{"id":"1113691420","title":"Cloudbreak-B (02592) Issues 1.785 Million Shares Under 2023 Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1113691420","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113691420?lang=en_us&edition=fundamental","pubTime":"2026-01-04 18:54","pubTimestamp":1767524050,"startTime":"0","endTime":"0","summary":"Cloudbreak-B (02592) announced that on January 3, 2026, it allotted and issued 1.785 million shares pursuant to its 2023 equity incentive plan.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":74,"code":"91000000","status":"200"}]}}